Acme's Mannitol IV Infusion 20%

Acme’s Mannitol IV Infusion is a potent osmotic diuretic containing 20% Mannitol, manufactured by ACME Laboratories Ltd. Priced at ৳155.47 per unit, this IV Infusion formulation primarily treats renal insufficiency, cerebral edema, and elevated intraocular pressure. Its mechanism involves increasing urine output to flush toxins and reduce fluid buildup in critical tissues.

This solution requires careful storage between 20°C–30°C. Crystallization at lower temperatures necessitates warming in hot water before use. Administration guidelines vary by age: adults receive 50–100g doses, while pediatric doses calculate 2g/kg body weight. Rapid infusion (30–60 mins) is critical for cerebral emergencies.

Common side effects include electrolyte imbalance, nausea, and tachycardia. Contraindications include severe dehydration and pulmonary edema. Pregnant women should use it cautiously due to limited safety data. The drug interactions section advises monitoring with nephrotoxic medications.

For bowel preparation or abortion induction, 50g Mannitol demonstrates therapeutic versatility. Clinicians prefer this brand for its reliability in managing poisoning cases and preventing hemolysis during urological surgeries. Explore alternative Mannitol brands or other IV therapies for comparative analysis.

Adults: 50-100g IV infusion daily. Pediatrics: 2g/kg over 2-6 hrs. Cerebral edema: 1.5-2g/kg over 30-60 mins. Poisoning: Maintain 100-500ml/hr urine output. For abortion: 50g intra-amniotic instillation.

The most common side effects associated with Acme’s Acme’s Mannitol intravenous infusion is fluid and electrolytes imbalance including circulatory overload and acidosis at high doses. Other side effects include nausea, vomiting, thirst, headache, dizziness, fever, tachycardia, chest pain, hyponatraemia, dehydration, blurred vision, urticaria, and hypertension or hypotension.

Pregnancy safety unestablished. Avoid during lactation. Use only if potential benefit justifies fetal risk.

Monitor fluid balance in cardiac/renal patients. Maintain infusion rate 50-100ml/hr. Do not mix with blood products. Redissolve crystals by warming if precipitated.

Start with reduced doses in elderly. Adjust dose in renal impairment. No specific hepatic dose adjustment. Pediatric dosing based on body weight.